We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF
IHE

97 hedge funds and large institutions have $348M invested in iShares US Pharmaceuticals ETF in 2017 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 26 increasing their positions, 35 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 11

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

26% more capital invested

Capital invested by funds: $276M → $348M (+$71.3M)

24.64% more ownership

Funds ownership: 120.84% → 145.48% (+25%)

5% more funds holding

Funds holding: 92 → 97 (+5)

26% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 35

Holders
97
Holders Change
+5
Holders Change %
+5.43%
% of All Funds
2.41%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
17
Increased
26
Reduced
35
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
CI
Clal Insurance
Israel
+$66.8M
2
MTWSIF
Mivtachim The Workers Social Insurance Fund
Israel
+$5.69M
3
MIAN
Mariner Independent Advisor Network
Kansas
+$5.41M
4
TSS
Two Sigma Securities
New York
+$5.39M
5
CS
Credit Suisse
Switzerland
+$4.03M

Top Sellers

1
BWL
Bogart Wealth LLC
Virginia
-$12.4M
2
Bank of America
Bank of America
North Carolina
-$8.87M
3
Morgan Stanley
Morgan Stanley
New York
-$6.58M
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$2.68M
5
TC
Telemus Capital
Michigan
-$2.31M
Name Holding Trade Value Shares
Change 		Change in
Stake
GLRA
51
Gerald L. Ray & Associates
Texas
$368K +$99.5K +2,010 +38%
PAG
52
Private Advisor Group
New Jersey
$361K -$102K -2,055 -22%
Creative Planning
53
Creative Planning
Kansas
$335K +$41.6K +840 +14%
TFA
54
Transamerica Financial Advisors
Florida
$308K -$2.23K -45 -0.7%
OC
55
Oppenheimer & Co
New York
$300K -$2.82K -57 -0.9%
JMPWA
56
JP Morgan Private Wealth Advisors
California
$299K +$294K +5,943 New
AG
57
Advisor Group
Arizona
$297K +$122K +2,463 +71%
BF
58
BOK Financial
Oklahoma
$291K – – –
CB
59
Commerce Bank
Missouri
$284K -$52.7K -1,065 -16%
EC
60
Estate Counselors
Wisconsin
$272K – – –
HSBC Holdings
61
HSBC Holdings
United Kingdom
$256K -$252K -5,091 -50%
RMAM
62
Raab & Moskowitz Asset Management
New Jersey
$243K -$93K -1,878 -28%
Cambridge Investment Research Advisors
63
Cambridge Investment Research Advisors
Iowa
$237K -$92.8K -1,875 -28%
CIBC World Market
64
CIBC World Market
Ontario, Canada
$234K -$354K -7,143 -61%
FAAS
65
First Allied Advisory Services
California
$234K -$93K -1,878 -29%
Bank of New York Mellon
66
Bank of New York Mellon
New York
$215K +$212K +4,278 New
RSA
67
Robertson Stephens Advisors
California
$206K +$203K +4,101 New
SWP
68
Stratos Wealth Partners
Ohio
$206K +$203K +4,104 New
EWM
69
Edge Wealth Management
New York
$200K -$31.6K -639 -14%
Citigroup
70
Citigroup
New York
$181K -$112K -2,268 -39%
CPA
71
Clear Perspective Advisors
Illinois
$143K -$11.1K -225 -7%
PNC Financial Services Group
72
PNC Financial Services Group
Pennsylvania
$102K +$149 +3 +0.1%
US Bancorp
73
US Bancorp
Minnesota
$101K -$543K -10,971 -85%
MWM
74
MinichMacGregor Wealth Management
New York
$93K – – –
ADL
75
Asset Dedication LLC
California
$81K – – –
1 2
3
4 5

IHE Hedge Fund Activity: Q1 2017 in Review

97 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q1 2017, worth a combined $348M — up 26% from $276M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new IHE positions and 11 closed out — a net gain of 6 holders — while 26 added to existing stakes and 35 trimmed.

The largest buyer was Clal Insurance, adding an estimated $66.8M. The largest seller was Bogart Wealth LLC, exiting entirely with an estimated $12.4M sold.

  • 97 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q1 2017, up from 92 in Q4 2016.
  • Funds reported $348M of iShares US Pharmaceuticals ETF stock for Q1 2017, up 26% quarter-over-quarter.
  • 17 funds opened new iShares US Pharmaceuticals ETF positions in Q1 2017 and 11 closed out, a net change of +6 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q1 2017 was Clal Insurance, an estimated $66.8M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q1 2017 was Bogart Wealth LLC, an estimated $12.4M sold.

Based on aggregated 13F filings for Q1 2017.